Gyros AB announces license and development agreement with Fujirebio Inc, Japan
Uppsala, Sweden, November 25, 2004 Gyros AB announced today that it has signed a non-exclusive license and development agreement with Fujirebio Inc. for diagnostic applications using Gyros’ proprietary Compact Disc technology.Under the terms of the agreement, Fujirebio will investigate combining Gyros’ Compact Disc technology with its own chemiluminescence immunoassay platform, in order to develop a new system for diagnostic applications. Jan Würtz, CEO & President of Gyros AB said; “Gyros has now reached an important milestone in its effort of commercialize its unique microfluidics